SCHEMBL21499646

SCHEMBL21499646

COc1ccc(CN2C(=O)C=C(/N=C/N(C)C)N(C)C2O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
GSK3A P49840 2/20 0.39
GSK3B P49841 2/20 0.39
KDM4E B2RXH2 3/20 0.38
HKDC1 Q2TB90 1/20 0.38
CMA1 P23946 1/20 0.37
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
HDAC6 Q9UBN7 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
MMP1 P03956 3/20 0.35
MMP9 P14780 2/20 0.35
MMP3 P08254 1/20 0.35
MMP13 P45452 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18457574 0.79 PDE5A (0.36) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL21499667 0.77 GSK3A (0.46) GSK3AGSK3BKDM4EHKDC1CMA1
SCHEMBL2644221 0.68 KDM4E (0.50) GSK3AGSK3BKDM4EHKDC1CMA1
SCHEMBL21316304 0.67 KDM4E (0.46) GSK3AGSK3BKDM4EHKDC1CMA1
SCHEMBL31148998 0.67 GSK3A (0.55) GSK3AGSK3BKDM4EHKDC1CMA1
SCHEMBL16028161 0.65 LMNA (0.61) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL16028158 0.65 LMNA (0.61) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL2644191 0.64 KDM4E (0.48) GSK3AGSK3BKDM4EHKDC1CMA1
SCHEMBL16364011 0.64 CMA1 (0.47) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL21847080 0.62 KDM4E (0.51) GSK3AGSK3BKDM4EHKDC1CMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230040259-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2023-02-09 US disclosed
US-11208409-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, LLC (US) 2021-12-28 US disclosed
US-20190322667-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230040259-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 PDE5A 461/4885PDE4A 615/4885PDE4B 583/4885
US-11208409-B2 Substituted xanthines and methods of use thereof TRPC5, TRPC7, TRPC4 PDE5A 461/4885PDE4A 615/4885PDE4B 583/4885
US-20190322667-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 PDE5A 461/4885PDE4A 615/4885PDE4B 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.